EP Patent

EP3659618A1 — Uses of aromatic-cationic peptide

Assigned to Institut de Recherches Cliniques de Montreal IRCM · Expires 2020-06-03 · 6y expired

What this patent protects

The present invention relates to a specific aromatic-cationic peptide and its use in reducing the number of mitochondria undergoing mitochondrial permeability transition (MPT), or preventing mitochondrial permeability transitioning in a mammal.

USPTO Abstract

The present invention relates to a specific aromatic-cationic peptide and its use in reducing the number of mitochondria undergoing mitochondrial permeability transition (MPT), or preventing mitochondrial permeability transitioning in a mammal.

Drugs covered by this patent

elamipretide-hydrochloride (ELAMIPRETIDE HYDROCHLORIDE)

Patent Metadata

Patent number: EP3659618A1
Jurisdiction: EP
Classification: —
Expires: 2020-06-03
Drug substance claim: No
Drug product claim: No
Assignee: Institut de Recherches Cliniques de Montreal IRCM
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.